Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Lycopene in Preventing Prostate Cancer in Healthy Participants

NCT00093561
View directory record Official record
Conditions
Prostate Cancer
Interventions
lycopene
Dietary Supplement
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

NCT02603770
View directory record Official record
Conditions
Lipid Metabolism Disorder
Interventions
XueZhiKang, Lovastatin
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Not applicable Interventional

MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients

NCT00165386
View directory record Official record
Conditions
Prostate Cancer
Interventions
Magnetic Resonance Imaging, Bone Marrow Biopsy
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

NCT05658146
View directory record Official record
Conditions
Healthy Participants
Interventions
Mavacamten Capsule 1, Mavacamten Capsule 2, Mavacamten Capsule 3
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 19, 2026, 4:16 PM EDT
Recruiting Phase 1 Interventional

A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body

NCT07525960
View directory record Official record
Conditions
Diabetes Insipidus
Interventions
NDI-5001
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220, Placebo
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 19, 2026, 4:16 PM EDT
Terminated Phase 2 Interventional Results available

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

NCT02473445
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Cysteamine Bitartrate
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
San Diego, California • Stanford, California • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

NCT03247530
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 100mg SPN-812, 200mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults

NCT05040295
View directory record Official record
Conditions
Healthy Participants
Interventions
ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020

NCT05045833
View directory record Official record
Conditions
Enteritis Caused by Radiation
Interventions
SYN-020 Delayed Release Capsule
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

NCT00002374
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Stavudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

NCT04054206
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MN-166
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study

NCT01220817
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
3 POMx capsules, 1 POMx capsule
Drug
Lead sponsor
POM Wonderful LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Results available

Does PAI Reduce Pain After TKA Among Knee Arthroplasty Patients Receiving ACB & IPACK?

NCT04749615
View directory record Official record
Conditions
Total Knee Athroplasty
Interventions
Periarticular Injection (PAI), Saline Control Periarticular Injection (PAI)
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
25 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

NCT00901498
View directory record Official record
Conditions
Alzheimer's Disease, Healthy
Interventions
BMS-708163
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

NCT05816356
View directory record Official record
Conditions
Healthy
Interventions
Decitabine, Tetrahydrouridine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of LY3154207 in Healthy Participants

NCT03942029
View directory record Official record
Conditions
Healthy
Interventions
LY3154207 Capsule, LY3154207 Tablet, Placebo, Fluconazole Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 19, 2026, 4:16 PM EDT
Terminated Phase 2 Interventional

A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

NCT00437164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
Insulin, Oral GW677954 Capsules (15 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 2 Interventional

A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma

NCT00002212
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Bexarotene
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Palm Springs, California • New Orleans, Louisiana • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 4:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule

NCT07219537
View directory record Official record
Conditions
Lynch Syndrome, Crohn Disease, Inflammatory Bowel Diseases, Healthy
Interventions
Feasibility of using an OCT-based Retrograde Tethered Capsule Endomicroscope device to image the lower GI tract
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 19, 2026, 4:16 PM EDT
Terminated Phase 3 Interventional Results available

Muscadine Plus (MPX) In Men With Prostate Cancer

NCT03535675
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Muscadine Plus, Placebos
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Duarte, California • La Jolla, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity

NCT04222322
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Epitomee Capsule, Control-Placebo
Device · Other
Lead sponsor
Epitomee medical
Industry
Eligibility
18 Years to 70 Years
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Results available

Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

NCT02178540
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, Tobi Podhaler
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 19, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

NCT02559310
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 19, 2026, 4:16 PM EDT